España
Italia
대한민국
日本
Français
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
Italia
대한민국
日本
Français
Login
Register
Premium Services
Financial News
Latest
Earnings
Guidance
Dividends
M&A
Buybacks
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Small-Cap
Markets
Pre-Market
After Hours
Movers
ETFs
Options
Cryptocurrency
Commodities
Bonds
Futures
Mining
Real Estate
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Investing Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
Analyst Ratings
Analyst Color
Latest Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Markets
Pre-Market
After Hours
Movers
ETFs
Options
Cryptocurrency
Commodities
Bonds
Futures
Mining
Real Estate
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Investing Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
Analyst Ratings
Analyst Color
Latest Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Recent
Markets
Valeant
$1,000, 5 Years Later: Valeant's Wild Ride To Bausch Health
Bausch Sees Clearer With Less Debt
Valeant's CEO Details The Company's 'Great Progress' And What's Next
Bausch Sees Clearer With Less Debt
Valeant's CEO Details The Company's 'Great Progress' And What's Next
Valeant Investors: Cantor Says It's Time To Stop Waiting For The Other Shoe To Drop
Valeant's $930 Million iNova Pharma Sale Boosts Stock Price
Valeant Investors: Cantor Says It's Time To Stop Waiting For The Other Shoe To Drop
Valeant's $930 Million iNova Pharma Sale Boosts Stock Price
Valeant Soars 14% After Encouraging Q1, Raised Guidance
Valeant's SILIQ Will Be Priced At $3,500 A Month
Read More...
Valeant Recent News
Bill Ackman Is Killin' It In Chipotle
Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook
Valeant's Post-Ackman Recovery Is Characterized By 'Less Money, More Problems'
Valeant: Traders Vs. Portfolio Managers
Pershing Square Defends Valeant's Progress, Can't Defend Its Stock Performance
Valeant's Asset Sale To L'Oreal Explained
Valeant's Laundry List: Products, Divestitures And Debt Load
Valeant Shares Carry Too Much Risk To Be Recommended As An Investment: Wells Fargo
Bill Ackman's Pershing Square Releases Q3 Letter To Shareholders
Criminal Charges Against Former Valeant Exec 'Not Pertinent But Underscores Cautious Outlook'
Is Allergan Going After Valeant's Eye Surgery Assets?
Analysts Having Difficulty Getting Comfortable With Valeant's Fundamentals
What Did Valeant Look Like Last Time The Stock Was Under $15?
A Deeper Look Into Valeant's Assets As It Searches For Salix Buyer
Valeant's Salix Story: To Sell Or Not To Sell?
Ackman: Valeant Doesn't Have To Sell Core Assets
Valeant Management On Q1 Call: 'We Don't Feel We Can Accurately Predict' GAAP Earnings
Can Broadcom Or Medtronic Offer Up An Earnings Surprise?
Report: Valeant Rejected A Takeover Offer Prior To Hiring Papa As CEO
Piper Jaffray Analyst: Latest Report On Valeant 'Doesn't Surprise Me'
Valeant's Price Cut To Hospitals Just Lip Service?
Ackman: Valeant Made Some Mistakes, But It's Not A Sewer
Senator Calls Out Bill Ackman, Questions His Senate Hearing Comments On Drug Pricing
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started